3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Sunitinib
145
Nivolumab
144
pembrolizumab
132
Sorafenib
84
Bevacizumab
77
Everolimus
74
cabozantinib
71
pazopanib
65
Axitinib
65
Ipilimumab
62
aldesleukin
52
Magnetic Resonance Spectroscopy
45
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
37
Specimen Handling
36
Radiosurgery
36
Interferon-alpha
32
atezolizumab
30
temsirolimus
27
belzutifan
24
Gemcitabine
23
fludarabine phosphate
22
avelumab
22
Radiotherapy
19
Interferon alpha-2
19
Biopsy
18
fludarabine
17
durvalumab
17
Nephrectomy
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Folfox protocol
×
Genitourinary
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled